Crossref
journal-article
Elsevier BV
Annals of Oncology (78)
References
128
Referenced
272
10.1038/277665a0/ Nature / Promotion of microtubule assembly in vitro by taxol by Schiff (1979)10.1021/ja00738a045/ J Am Chem Soc / Plant antitumor agents VI. The isolation and structure of taxol: a novel antileukemic and antitumour agent from Taxus brevifolia by Wani (1971)10.1016/S0140-6736(94)90754-4/ Lancet / The taxoids: paclitaxel and docetaxel by Gelmon (1994)10.2165/00002018-200023050-00005/ Drug Safety / Risks and benefits of taxanes in breast and ovarian cancer by Boehnke Michaud (2000)10.2165/00003088-200342070-00005/ Clin Pharmacokinet / Pharmacological effects of formulation vehicles: implications for cancer chemotherapy by ten Tije (2003)10.1200/JCO.1990.8.7.1263/ J Clin Oncol / Hypersensitivity reactions from taxol by Weiss (1990){'key': '10.1093/annonc/mdj100_bb0040', 'first-page': '2486', 'article-title': 'Phase I clinical and pharmacokinetic study of taxol', 'volume': '47', 'author': 'Wiernik', 'year': '1987', 'journal-title': 'Cancer Res'}/ Cancer Res / Phase I clinical and pharmacokinetic study of taxol by Wiernik (1987)10.1007/BF01964882/ Agents Actions / Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent by Lorenz (1977)10.1345/aph.19383/ Ann Pharmacother / Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions by Bernstein (2000)10.1177/106002809703101120/ Ann Pharmacother / Methods for preventing reactions secondary to Cremophor EL by Michaud (1997){'key': '10.1093/annonc/mdj100_bb0060', 'first-page': '1', 'article-title': 'Clinical toxicities encountered with paclitaxel (Taxol)', 'volume': '20', 'author': 'Rowinsky', 'year': '1993', 'journal-title': 'Semin Oncol'}/ Semin Oncol / Clinical toxicities encountered with paclitaxel (Taxol) by Rowinsky (1993){'key': '10.1093/annonc/mdj100_bb0065', 'first-page': '131', 'article-title': 'Overview of Taxol safety', 'volume': '15', 'author': 'Onetto', 'year': '1993', 'journal-title': 'J Natl Cancer Inst'}/ J Natl Cancer Inst / Overview of Taxol safety by Onetto (1993){'key': '10.1093/annonc/mdj100_bb0070', 'first-page': '861', 'article-title': 'Central nervous system toxicity after liver transplantation', 'volume': '317', 'author': 'de Groen', 'year': '1987', 'journal-title': 'The role of cyclosporine and cholesterol. N Engl J Med'}/ The role of cyclosporine and cholesterol. N Engl J Med / Central nervous system toxicity after liver transplantation by de Groen (1987){'key': '10.1093/annonc/mdj100_bb0075', 'first-page': '1051', 'article-title': 'Potential neurotoxicity of the solvent vehicle for cyclosporine', 'volume': '268', 'author': 'Windebank', 'year': '1994', 'journal-title': 'J Pharmacol Exp Ther'}/ J Pharmacol Exp Ther / Potential neurotoxicity of the solvent vehicle for cyclosporine by Windebank (1994){'key': '10.1093/annonc/mdj100_bb0080', 'first-page': '803', 'article-title': 'Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E', 'volume': '261', 'author': 'Brat', 'year': '1992', 'journal-title': '115 neuroblastoma. J Pharmacol Exp Ther'}/ 115 neuroblastoma. J Pharmacol Exp Ther / Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E by Brat (1992){'key': '10.1093/annonc/mdj100_bb0085', 'first-page': '2112', 'article-title': 'Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL', 'volume': '56', 'author': 'Sparreboom', 'year': '1996', 'journal-title': 'Cancer Res'}/ Cancer Res / Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL by Sparreboom (1996)10.1038/sj.bjc.6690696/ Br J Cancer / Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients by van Tellingen (1999){'key': '10.1093/annonc/mdj100_bb0095', 'first-page': '1454', 'article-title': 'Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications', 'volume': '59', 'author': 'Sparreboom', 'year': '1999', 'journal-title': 'Cancer Res'}/ Cancer Res / Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications by Sparreboom (1999)10.1200/JCO.2004.08.048/ J Clin Oncol / Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342 by Winer (2004)10.1200/jco.2004.22.14_suppl.512/ Proc Am Soc Clin Oncol / CALGB 9840 phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC) with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC by Seidman (2004)10.1200/JCO.2005.05.031/ . J Clin Oncol / “Will weekly work”? seems to be so by Seidman (2005)10.1200/JCO.2005.06.232/ J Clin Oncol / Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks by Green (2005)10.1023/A:1010618632738/ Invest New Drugs / Role of formulation vehicles in taxane pharmacology by van Zuylen (2001){'key': '10.1093/annonc/mdj100_bb0125', 'first-page': '2918', 'article-title': 'Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and its metabolites in mice', 'volume': '5', 'author': 'van Tellingen', 'year': '1999', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and its metabolites in mice by van Tellingen (1999)10.1016/S0009-9236(03)00222-4/ Clin Pharmacol Ther / Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins by Loos (2003)10.1158/1078-0432.CCR-0842-03/ Clin Cancer Res / Comparative pharmacokinetics of weekly and every-three-weeks docetaxel by Baker (2004){'issue': '14', 'key': '10.1093/annonc/mdj100_bb0140', 'first-page': '4199', 'article-title': 'Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs', 'volume': '50', 'author': 'Woodcock', 'year': '1990', 'journal-title': 'Cancer Res'}/ Cancer Res / Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs by Woodcock (1990)10.1038/bjc.1990.335/ Br J Cancer / The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance by Schuurhuis (1990){'key': '10.1093/annonc/mdj100_bb0150', 'first-page': '297', 'article-title': 'The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor', 'volume': '2', 'author': 'Friche', 'year': '1990', 'journal-title': 'Cancer Commun'}/ Cancer Commun / The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor by Friche (1990)10.1038/bjc.1997.530/ Br J Cancer / Enhanced oral bioavailability of paclitaxel in mice treated with the p-glycoprotein blocker SDZ PSC 833 by van Asperen (1997){'key': '10.1093/annonc/mdj100_bb0160', 'first-page': '775', 'article-title': 'Cyclosporin a strongly enhances the oral bioavailability of docetaxel in cancer patients', 'volume': '17', 'author': 'Richel', 'year': '1999', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Cyclosporin a strongly enhances the oral bioavailability of docetaxel in cancer patients by Richel (1999)10.1200/JCO.2000.18.12.2468/ J Clin Oncol / pharmacokinetic study of oral paclitaxel by Malingre (2000)10.1016/0959-8049(94)90546-0/ Eur J Cancer / Paclitaxel-induced cytotoxicity—the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein by Fjallskog (1994)10.1016/0140-6736(93)92735-C/ Lancet / Is Cremophor EL, solvent for paclitaxel, cytotoxic? by Fjallskog (1993)10.1007/BF00685909/ Cancer Chemother Pharmacol / The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines by Liebmann (1994)10.1007/BF00689711/ Breast Cancer Res Treat / Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and vitamin-E by Chajes (1995)10.1093/jn/132.7.2069/ J Nutr / Carp oil or oleic acid, but not linoleic acid or linolenic acid, inhibits tumor growth and metastasis in Lewis lung carcinoma-bearing mice by Kimura (2002)10.1023/A:1010682916808/ Invest New Drugs / Progress in the development of alternative pharmaceutical formulations of taxanes by Nuijen (2001){'key': '10.1093/annonc/mdj100_bb0200', 'first-page': '1038', 'article-title': 'Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized', 'volume': '8', 'author': 'Ibrahim', 'year': '2002', 'journal-title': 'nanoparticle formulation of paclitaxel. Clin Cancer Res'}/ nanoparticle formulation of paclitaxel. Clin Cancer Res / Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized by Ibrahim (2002){'key': '10.1093/annonc/mdj100_bb0205', 'first-page': '348', 'article-title': 'Evidence of greater antitumor activity of cermophor-free nanoparticle albumin-bound (nab) paclitaxel (abraxane) compared to taxol role of a novel albumin transporter mechanism', 'volume': '92', 'author': 'Desai', 'year': '2003', 'journal-title': 'Breast Cancer Res Treat'}/ Breast Cancer Res Treat / Evidence of greater antitumor activity of cermophor-free nanoparticle albumin-bound (nab) paclitaxel (abraxane) compared to taxol role of a novel albumin transporter mechanism by Desai (2003){'key': '10.1093/annonc/mdj100_bb0210', 'first-page': '462', 'article-title': 'Evidence of enhanced in vivo efficacy at maximum tolerated dose (MTD) of nanoparticle paclitaxel (ABI-007) and taxol in 5 human xenografts of varying sensitivity to paclitaxel', 'volume': '20', 'author': 'Desai', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Evidence of enhanced in vivo efficacy at maximum tolerated dose (MTD) of nanoparticle paclitaxel (ABI-007) and taxol in 5 human xenografts of varying sensitivity to paclitaxel by Desai (2002){'key': '10.1093/annonc/mdj100_bb0215', 'first-page': '348', 'article-title': 'Evidence of greater tumor and red cell partitioning and superior antitumor activity of cremophor free nanoparticle paclitaxel (ABI-007) compared to taxol', 'volume': '82', 'author': 'Desai', 'year': '2003', 'journal-title': 'Breast Cancer Res Treat'}/ Breast Cancer Res Treat / Evidence of greater tumor and red cell partitioning and superior antitumor activity of cremophor free nanoparticle paclitaxel (ABI-007) compared to taxol by Desai (2003)10.1200/jco.2004.22.14_suppl.2027/ Proc Am Soc Clin Oncol / A phase I trial of ABI-007 nanoparticle paclitaxel administered to patients with advanced non-hematologic malignancies by Nyman (2004)10.1002/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO;2-4/ Cancer / Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007) by Damascelli (2001)10.2214/ajr.181.1.1810253/ Am J Roentgenol / A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings by Damascelli (2003){'key': '10.1093/annonc/mdj100_bb0235', 'first-page': '209', 'article-title': 'Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer efficacy and evidence of dose-dependent activity in two multicenter phase II studies', 'volume': '20', 'author': 'Ibrahim', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer efficacy and evidence of dose-dependent activity in two multicenter phase II studies by Ibrahim (2002)10.1200/jco.2004.22.90140.543/ Proc Am Soc Clin Oncol / Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel by Blum (2004)10.1200/JCO.2005.04.937/ J Clin Oncol / Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor-oil-based paclitaxel in women with metastatic breast cancer: results of a phase III trial by Gradishar (2005){'key': '10.1093/annonc/mdj100_bb0250', 'first-page': '3589', 'article-title': 'Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile', 'volume': '9', 'author': 'Wolff', 'year': '2003', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile by Wolff (2003){'key': '10.1093/annonc/mdj100_bb0255', 'first-page': '3229', 'article-title': 'Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel', 'volume': '7', 'author': 'Bradley', 'year': '2001', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel by Bradley (2001){'key': '10.1093/annonc/mdj100_bb0260', 'first-page': '151', 'article-title': 'Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies', 'volume': '9', 'author': 'Sparreboom', 'year': '2003', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies by Sparreboom (2003)10.1038/sj.bjc.6602196/ Br J Cancer / Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumors by Harries (2004)10.1200/jco.2004.22.14_suppl.7111/ Proc Am Soc Clin Oncol / Safety and efficacy of DHA-paclitaxel (TXP) in non-small cell lung cancer by Schacter (2004)10.1200/jco.2004.22.14_suppl.4657/ Proc Am Soc Clin Oncol / Phase II study of DHA-paclitaxel as first line chemotherapy in patients with hormone refractory prostate cancer by Bellet (2004){'key': '10.1093/annonc/mdj100_bb0280', 'first-page': '65', 'article-title': 'Efficacy of DHA-paclitaxel (TXP) for the second line treatment of breast cancer', 'volume': '22', 'author': 'Johnston', 'year': '2004', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Efficacy of DHA-paclitaxel (TXP) for the second line treatment of breast cancer by Johnston (2004){'key': '10.1093/annonc/mdj100_bb0285', 'first-page': '1090', 'article-title': 'Efficacy of DHA-paclitaxel in pancreatic cancer', 'volume': '21', 'author': 'Jacobs', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Efficacy of DHA-paclitaxel in pancreatic cancer by Jacobs (2003){'key': '10.1093/annonc/mdj100_bb0290', 'first-page': '2891', 'article-title': 'Efficacy of DHA-paclitaxel in malignant melanoma', 'volume': '21', 'author': 'Modiano', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Efficacy of DHA-paclitaxel in malignant melanoma by Modiano (2003){'key': '10.1093/annonc/mdj100_bb0295', 'first-page': '1154', 'article-title': 'Efficacy of DHA-paclitaxel in adenocarcinoma of the esophagus or stomach', 'volume': '21', 'author': 'Evans', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Efficacy of DHA-paclitaxel in adenocarcinoma of the esophagus or stomach by Evans (2003){'key': '10.1093/annonc/mdj100_bb0300', 'series-title': 'Polymer Drugs in the Clinical Stage', 'first-page': '81', 'article-title': 'Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data', 'author': 'Singer', 'year': '2003'}/ Polymer Drugs in the Clinical Stage / Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data by Singer (2003)10.1016/S0169-409X(02)00045-5/ Adv Drug Deliv Rev / Poly(L-glutamic acid): anticancer drug conjugates by Li (2002)10.1200/JCO.2004.12.043/ J Clin Oncol / Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma by Sabbatini (2004){'key': '10.1093/annonc/mdj100_bb0315', 'first-page': '2404', 'article-title': 'Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate', 'volume': '58', 'author': 'Li', 'year': '1998', 'journal-title': 'Cancer Res'}/ Cancer Res / Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate by Li (1998){'key': '10.1093/annonc/mdj100_bb0320', 'first-page': '891', 'article-title': 'Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors', 'volume': '5', 'author': 'Li', 'year': '1999', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors by Li (1999)10.1016/S0360-3016(02)04153-6/ Int J Radiat Oncol Biol Phys / Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability by Milas (2003){'key': '10.1093/annonc/mdj100_bb0330', 'first-page': '2829', 'article-title': 'Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy', 'volume': '6', 'author': 'Li', 'year': '2000', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy by Li (2000)10.1016/S0360-3016(00)00757-4/ Int J Radiat Oncol Biol Phys / Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate by Li (2000){'key': '10.1093/annonc/mdj100_bb0340', 'first-page': '533', 'article-title': 'Phase I pharmacokinetic study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors', 'volume': '21', 'author': 'Verrill', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase I pharmacokinetic study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors by Verrill (2003){'key': '10.1093/annonc/mdj100_bb0345', 'first-page': '2833', 'article-title': 'Phase I study of CT-2103 in patients with non-small cell lung cancer', 'volume': '21', 'author': 'Shipley', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase I study of CT-2103 in patients with non-small cell lung cancer by Shipley (2003){'key': '10.1093/annonc/mdj100_bb0350', 'first-page': '646', 'article-title': 'Phase I study of CT-2103/carboplatin in patients with solid tumors', 'volume': '21', 'author': 'Bolton', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase I study of CT-2103/carboplatin in patients with solid tumors by Bolton (2003){'key': '10.1093/annonc/mdj100_bb0355', 'first-page': '1841', 'article-title': 'Phase I study of CT-2103/cisplatin in patients with solid tumors', 'volume': '21', 'author': 'Kudelka', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase I study of CT-2103/cisplatin in patients with solid tumors by Kudelka (2003)10.1200/JCO.2000.18.5.1062/ J Clin Oncol / Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a gynecologic oncology group study by McGuire (2000)10.1200/JCO.2001.19.7.1893/ J Clin Oncol / Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer by Gore (2001)10.1016/S1359-6349(03)90831-7/ Eur J Cancer Suppl / Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small cell lung cancer who are >69 years of age or who have performance status (PS) = 2 by Bodkin (2003){'key': '10.1093/annonc/mdj100_bb0375', 'first-page': '1137', 'article-title': 'Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-flourouracil-containing regimen', 'volume': '21', 'author': 'Schulz', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-flourouracil-containing regimen by Schulz (2003){'key': '10.1093/annonc/mdj100_bb0380', 'first-page': '169', 'article-title': 'A phase 2 study of CT-2103 a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks in patients with advanced breast cancer', 'volume': '21', 'author': 'Robson', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / A phase 2 study of CT-2103 a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks in patients with advanced breast cancer by Robson (2003)10.1634/theoncologist.9-4-398/ Oncologist / Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax) by Langer (2004){'key': '10.1093/annonc/mdj100_bb0390', 'article-title': 'Paclitaxel poligulmex/carboplain vs. paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer: A phase III study', 'volume': '23', 'author': 'Langer', 'year': '2005', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Paclitaxel poligulmex/carboplain vs. paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer: A phase III study by Langer (2005)10.1021/jm0102607/ J Med Chem / Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476 by Altstadt (2001)10.1007/s002800000241/ Cancer Chemother Pharmacol / Preclinical antitumor activity of two novel taxanes by Rose (2001)10.1016/S0360-3016(01)01658-3/ Int J Radiat Oncol Biol Phys / The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells by Kim (2001)10.1200/JCO.2001.19.9.2493/ J Clin Oncol / Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel by Hidalgo (2001){'key': '10.1093/annonc/mdj100_bb0415', 'first-page': '2788', 'article-title': 'Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies', 'volume': '8', 'author': 'Plummer', 'year': '2002', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies by Plummer (2002){'key': '10.1093/annonc/mdj100_bb0420', 'first-page': '5221', 'article-title': 'Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days', 'volume': '9', 'author': 'Sun', 'year': '2003', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days by Sun (2003)10.1038/sj.bjc.6601885/ Br J Cancer / Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days by Bilenker (2004)10.1016/j.ejca.2003.11.023/ Eur J Cancer / Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin by Sessa (2004)10.1111/j.1349-7006.2003.tb01465.x/ Cancer Sci / DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo by Shionoya (2003)10.1248/bpb.27.345/ Biol Pharm Bull / Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys by Ono (2004)10.1200/jco.2004.22.14_suppl.2028/ Proc Am Soc Clin Oncol / Phase I and pharmacokinetics of DJ-927 an oral taxane in patients with advanced cancers by Syed (2004)10.1200/jco.2004.22.90140.2029/ Proc Am Soc Clin Oncol / A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors by Broker (2004){'key': '10.1093/annonc/mdj100_bb0455', 'first-page': '398', 'article-title': 'A new oral taxane (BMS-275183) phase I trial with evaluation of pharmacokinetics pharmacodynamics and bioavailability', 'volume': '20', 'author': 'Trump', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / A new oral taxane (BMS-275183) phase I trial with evaluation of pharmacokinetics pharmacodynamics and bioavailability by Trump (2002){'key': '10.1093/annonc/mdj100_bb0460', 'first-page': '2016', 'article-title': 'Preclinical pharmacology of BMS-275183', 'volume': '7', 'author': 'Rose', 'year': '2001', 'journal-title': 'an orally active taxane. Clin Cancer Res'}/ an orally active taxane. Clin Cancer Res / Preclinical pharmacology of BMS-275183 by Rose (2001)10.1158/1078-0432.CCR-04-1045/ Clin Cancer Res / Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts by Rose (2004){'key': '10.1093/annonc/mdj100_bb0470', 'first-page': '2647', 'article-title': 'Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer', 'volume': '8', 'author': 'Cassinelli', 'year': '2002', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer by Cassinelli (2002){'key': '10.1093/annonc/mdj100_bb0475', 'first-page': '1036', 'article-title': 'A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts', 'volume': '59', 'author': 'Polizzi', 'year': '1999', 'journal-title': 'Cancer Res'}/ Cancer Res / A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts by Polizzi (1999){'key': '10.1093/annonc/mdj100_bb0480', 'first-page': '2070', 'article-title': 'Oral efficacy and bioavailability of a novel taxane', 'volume': '6', 'author': 'Polizzi', 'year': '2000', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Oral efficacy and bioavailability of a novel taxane by Polizzi (2000){'key': '10.1093/annonc/mdj100_bb0485', 'first-page': '842', 'article-title': 'IDN5109, a taxane with oral bioavailability and potent antitumor activity', 'volume': '60', 'author': 'Nicoletti', 'year': '2000', 'journal-title': 'Cancer Res'}/ Cancer Res / IDN5109, a taxane with oral bioavailability and potent antitumor activity by Nicoletti (2000){'key': '10.1093/annonc/mdj100_bb0490', 'first-page': '647', 'article-title': 'A phase I and pharmacokinetic study of a novel taxane BAY 59-8862 with a weekly schedule', 'volume': '21', 'author': 'Laurence', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / A phase I and pharmacokinetic study of a novel taxane BAY 59-8862 with a weekly schedule by Laurence (2003){'key': '10.1093/annonc/mdj100_bb0495', 'first-page': '965', 'article-title': 'A phase I and pharmacokinetic study of a novel oral taxane BAY 59-8862 in solid tumors', 'volume': '21', 'author': 'Tonkin', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / A phase I and pharmacokinetic study of a novel oral taxane BAY 59-8862 in solid tumors by Tonkin (2003)10.1200/jco.2004.22.90140.7136/ Proc Am Soc Clin Oncol / An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59-8862) in patients with taxane-resistant non-small cell lung cancer by Gurtler (2004)10.1200/JCO.2000.18.24.4098/ J Clin Oncol / Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors by Gelmon (2000)10.1200/JCO.2000.18.17.3164/ J Clin Oncol / Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors by Kurata (2000){'key': '10.1093/annonc/mdj100_bb0515', 'first-page': '1882', 'article-title': 'In vivo isolation and characterization of a docetaxel resistant B16 melanoma', 'volume': '36', 'author': 'Bissery', 'year': '1995', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / In vivo isolation and characterization of a docetaxel resistant B16 melanoma by Bissery (1995)10.1093/annonc/mdf174/ Ann Oncol / Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors by Sessa (2002){'key': '10.1093/annonc/mdj100_bb0525', 'first-page': '747', 'article-title': 'A Phase I and pharmacokinetics study of RPR 109881A given as 6-hour iv infusion in patients with advanced solid tumors', 'volume': '16', 'author': 'Barthier', 'year': '1998', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / A Phase I and pharmacokinetics study of RPR 109881A given as 6-hour iv infusion in patients with advanced solid tumors by Barthier (1998){'key': '10.1093/annonc/mdj100_bb0530', 'first-page': '748', 'article-title': 'Phase I trial of RPR 109881A a novel taxoid derivative administered as a 24-hour continuous infusion', 'volume': '16', 'author': 'Slaughter', 'year': '1998', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase I trial of RPR 109881A a novel taxoid derivative administered as a 24-hour continuous infusion by Slaughter (1998){'key': '10.1093/annonc/mdj100_bb0535', 'first-page': '745', 'article-title': 'Phase I study of RPR 109881A in patients with advanced solid tumors', 'volume': '16', 'author': 'Hyodo', 'year': '1998', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase I study of RPR 109881A in patients with advanced solid tumors by Hyodo (1998){'key': '10.1093/annonc/mdj100_bb0540', 'first-page': '749', 'article-title': 'Pharmacokinetics of a new taxoid (RPR 109881A) comparison of five different administration schedules', 'volume': '16', 'author': 'Vernillet', 'year': '1998', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Pharmacokinetics of a new taxoid (RPR 109881A) comparison of five different administration schedules by Vernillet (1998){'key': '10.1093/annonc/mdj100_bb0545', 'first-page': '141', 'article-title': 'A multicentre non randomized phase II study with RPR 10988A in metastatic breast cancer patients', 'volume': '22', 'author': 'Dieras', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / A multicentre non randomized phase II study with RPR 10988A in metastatic breast cancer patients by Dieras (2003)10.1016/S0168-3659(01)00275-9/ J Control Release / In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy by Kim (2001)10.1097/00001813-199708000-00008/ Anticancer Drugs / Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel by Zhang (1997)10.1007/s002800050630/ Cancer Chemother Pharmacol / An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel by Zhang (1997)10.1158/1078-0432.CCR-03-0655/ Clin Cancer Res / Phase I and pharmacokinetic study of genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies by Kim (2004){'key': '10.1093/annonc/mdj100_bb0570', 'first-page': '2883', 'article-title': 'Liposomal encapsulated taxol is an effective modality to circumvent multidrug resistance phenotype', 'volume': '33', 'author': 'Rafaeloff', 'year': '1992', 'journal-title': 'Proc Am Assoc Cancer Res'}/ Proc Am Assoc Cancer Res / Liposomal encapsulated taxol is an effective modality to circumvent multidrug resistance phenotype by Rafaeloff (1992){'key': '10.1093/annonc/mdj100_bb0575', 'first-page': '1035', 'article-title': 'Comparative in vivo studies with paclitaxel and liposome encapsulated paclitaxel', 'volume': '12', 'author': 'Cabanes', 'year': '1998', 'journal-title': 'Int J Oncol'}/ Int J Oncol / Comparative in vivo studies with paclitaxel and liposome encapsulated paclitaxel by Cabanes (1998){'key': '10.1093/annonc/mdj100_bb0580', 'first-page': '44', 'article-title': 'Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel', 'volume': '15', 'author': 'Treat', 'year': '2001', 'journal-title': 'Oncology'}/ Oncology / Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel by Treat (2001){'key': '10.1093/annonc/mdj100_bb0585', 'first-page': '1862', 'article-title': 'Phase I trial in advanced malignancies with liposome encapsulated paclitaxel (LEP) Q 3 weeks', 'volume': '20', 'author': 'Bowden', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase I trial in advanced malignancies with liposome encapsulated paclitaxel (LEP) Q 3 weeks by Bowden (2002){'key': '10.1093/annonc/mdj100_bb0590', 'first-page': '404', 'article-title': 'Phase I and pharmacokinetic study of weekly schedule of LEP (liposomal encapsulated paclitaxel) in patients with solid tumors', 'volume': '20', 'author': 'Soepenberg', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase I and pharmacokinetic study of weekly schedule of LEP (liposomal encapsulated paclitaxel) in patients with solid tumors by Soepenberg (2002)10.1200/jco.2004.22.90140.2110/ Proc Am Soc Clin Oncol / Phase I study of lipsome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer by Fishman (2004){'key': '10.1093/annonc/mdj100_bb0600', 'first-page': '406', 'article-title': 'S-8184 vitamin E paclitaxel emulsion preclinical and phase I data', 'volume': '20', 'author': 'Spigel', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / S-8184 vitamin E paclitaxel emulsion preclinical and phase I data by Spigel (2002){'key': '10.1093/annonc/mdj100_bb0605', 'first-page': '988', 'article-title': 'Paclitaxel vitamin E emulsion phase I/II study of weekly administration in patients with non-small cell lung cancer transitional cell ovarian or colorectal cancer', 'volume': '21', 'author': 'Bogdanova', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Paclitaxel vitamin E emulsion phase I/II study of weekly administration in patients with non-small cell lung cancer transitional cell ovarian or colorectal cancer by Bogdanova (2003)10.1200/jco.2004.22.14_suppl.4586/ Proc Am Soc Clin Oncol / Paclitaxel injectable emulsion phase 2a study of weekly administration in patients with metastatic or locally advanced unresectable or recurrent urothelial transitional cell cancer by Gorelov (2004){'issue': 'Abstr', 'key': '10.1093/annonc/mdj100_bb0615', 'first-page': '22', 'article-title': 'Paclitaxel injectable emulsion: phase 2a study of weekly administration in patients with non-small cell lung cancer', 'volume': '7133', 'author': 'Bogdanova', 'year': '2004', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Paclitaxel injectable emulsion: phase 2a study of weekly administration in patients with non-small cell lung cancer by Bogdanova (2004)10.1200/jco.2004.22.14_suppl.5047/ Proc Am Soc Clin Oncol / Paclitaxel injectable emulsion phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer by Lissianskaya (2004){'key': '10.1093/annonc/mdj100_bb0625', 'first-page': '4242', 'article-title': 'Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice', 'volume': '5', 'author': 'Harper', 'year': '1999', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice by Harper (1999){'key': '10.1093/annonc/mdj100_bb0630', 'first-page': '3441', 'article-title': 'Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies', 'volume': '9', 'author': 'Li', 'year': '2003', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies by Li (2003)10.1002/pros.10331/ Prostate / Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation by Lapidus (2004)- Product Information: Abraxane, Paclitaxel Protein-Bound Particles. Schaumburg, IL: Abraxis Oncology, updated January 2005.
{'key': '10.1093/annonc/mdj100_bb0645', 'first-page': '64', 'article-title': 'ABI-007 nanoparticle paclitaxel demonostration of anti-tumor activity in taxane-refractory metastatic breast cancer', 'volume': '21', 'author': 'Blum', 'year': '2003', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / ABI-007 nanoparticle paclitaxel demonostration of anti-tumor activity in taxane-refractory metastatic breast cancer by Blum (2003)
Dates
| Type | When |
|---|---|
| Created | 19 years, 8 months ago (Dec. 19, 2005, 8:24 p.m.) |
| Deposited | 5 years, 6 months ago (Feb. 20, 2020, 11:53 a.m.) |
| Indexed | 3 weeks, 6 days ago (Aug. 2, 2025, 12:18 a.m.) |
| Issued | 19 years, 3 months ago (May 1, 2006) |
| Published | 19 years, 3 months ago (May 1, 2006) |
| Published Print | 19 years, 3 months ago (May 1, 2006) |
@article{Hennenfent_2006, title={Novel formulations of taxanes: a review. Old wine in a new bottle?}, volume={17}, ISSN={0923-7534}, url={http://dx.doi.org/10.1093/annonc/mdj100}, DOI={10.1093/annonc/mdj100}, number={5}, journal={Annals of Oncology}, publisher={Elsevier BV}, author={Hennenfent, K.L. and Govindan, R.}, year={2006}, month=may, pages={735–749} }